Introduction
Gene therapy is an ever broadening field generally defined as the transfer of genetic material with therapeutic intent. Since the first human in vivo gene transfer study in 1989, a variety of clinical trials involving gene transfer have been initiated. The most obvious application of gene therapy is correction of inherited genetic diseases, such as the hemoglobinopathies, immunodeficiency syndromes, and metabolic disorders. Over the past two decades, investigators have realized that gene transfer technology can provide novel approaches to a large variety of illnesses not traditionally thought of as genetic disease. The potential therapeutic benefit of gene therapy has been shown in an ever increasing database of laboratory and animal studies. The current challenge is to develop the technical skills necessary to apply this technology in a clinically safe and effective manner.
Hematopoietic stem cells remain attractive targets for gene therapy approaches. These cells are well suited to ex vivo manipulations, transplantation technology for this organ is well characterized, and a number of genetic, malignant and viral diseases can be targeted by gene transfer of hematopoietic cells. As one anticipates that hematopoietic progenitor cells will undergo extensive expansion, vectors with the ability to stably integrate into the target cell insure passage of the gene of interest to subsequent daughter cells. To date, retroviral vectors have been the vector of choice for transducing hematopoietic cells as they allow stable integration of vector sequences without significant cell death, chromosomal disruption, or other deleterious factors that may negatively impact on the viability of the target cell. Retroviruses were the basis for the first viral vectors developed [1] [2] [3] and the first viral vector to enter clinical trials. 4 Most retroviral vectors are based on the murine leukemia viruses (oncoretroviruses, subsequently referred to in this manuscript as retroviruses) and take advantage of the unique reproductive cycle of the retrovirus, which allows for the deletion of the viral protein coding sequences (gag, pol and env), and substitution of this region with an exogenous gene(s) of interest deletion of the viral protein coding sequences renders the vectors replication defective, a requirement for clinical application, but a technical problem in packaging vector RNA into virions. This challenge has been met through the development of retroviral packaging cell lines 5, 6 (see Miller  7 for a review). Initial packaging cell lines were generated from murine fibroblast cell lines, most commonly NIH3T3 cells. Plasmids expressing the genes required for virion formation (gag and pol) are transfected along with the cDNA for an envelope glycoprotein, which facilitates virion infection. These engineered cell lines act as factories for virion proteins but the plasmids are constructed so that the viral genes are unlikely to be incorporated into viral particles. Transfection of a plasmid containing the vector construct (ie the viral LTR and transgene of interest) results in production of vector particles that are released into the media. grade vectors for gene therapy trials. Currently, there are three production sites, Baylor College of Medicine supplies adenoviral vectors, the City of Hope Medical Center is the site for production of plasmid vectors, and Indiana University generated retroviral and lentiviral vectors. Two additional sites, the University of Florida and Southern Research Institute, supply toxicology studies in support of gene therapy clinical trials. The coordination site for the program is at Indiana University (www.ngvl.org). To date, the Indiana University Vector Production Facility has generated over 30 Master Cell Banks (MCB) for gene therapy investigators throughout the United States (Table 1 ). The facility is designed to produce vectors for Phase I and Phase II clinical trials.
The basic steps in vector production using retroviral packaging cells are shown above in Table 2 , which also provides a timetable for vector production and certification. While recent vector production requests have sought to utilize human cell lines, the majority of investigators have requested vectors produced by murine packaging cell lines. The NGVL has developed a method that reliably yields high titer vector producer cell clones suitable for MCB generation. We maintain certified MCBs of a variety of murine-derived (PA317, PG13, GPE+Am12, and GP+E86) and human-derived (Ampho-Phoenix and Eco-Phoenix) packaging cell lines. For generating producer cell lines such as PG13, we initially obtain a small but high titer vector preparation by the transient transfection method using the EcoPhoenix cell line (a 293-based cell line). This leads to infection of virtually every PG13 cell (unpublished data). The population of PG13 generated is usually suitable for preclinical use and allows us to provide investigators with high titer material without requiring clone selection. For clinical productions, the US FDA has generally required the producer cells to be of clonal origin, which does impose significant time and personnel requirements. Producer cell clones are generally isolated through limiting dilution clone selection or by singlecell sorting into a 96-well plate. After clones are isolated and expanded, their media is assayed by real-time PCR using a modification of our previously reported method 8 
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in which real-time PCR is utilized to detect the packaging sequence common to most retroviral vectors. Promising clones are further expanded and supernatant samples are sent to the investigator to evaluate function and transduction efficiency.
Once the optimal clone is agreed upon, an MCB of between 100 and 200 vials is generated. The MCB must be shown to be free of infectious agents or other contaminants. A list of certification tests that will be performed on a MCB is provided in Table 3 , although it should be noted that this is often a partial list as the precise testing requirements for an MCB will vary with the cell of origin, the intended use (ex vivo or in vivo), the transgene, and other potential variables. The optimal harvest conditions are then determined using cells from the MCB. We have previously reported that the PA317, PG13, and GPE+Am12 vector packaging cell line differ significantly from their parent cell line NIH3T3 cells. 9 These differences include different glucose utilization rates and doubling times, with PA317 and PG13 growing significantly faster than GPE+Am12 cells. Interestingly, all three packaging cell lines have developed the ability to form colonies in soft agar, suggesting a more transformed phenotype than the parent NIH3T3 cells that exhibit contact inhibition and does not form colonies in soft agar. 9 To optimize vector titer, we have also evaluated the role of temperature during the days of vector harvest. We confirmed the prior report of Kotani et al 10 indicating that producer cells derived from PA317 may have higher titer when material is harvested at 321C. In contrast, we noted that GPE+Am12 and PG13 may provide higher titer when maintained at 371C during the harvest period. Another observation was significant differences in the optimal timing between harvests. For example, optimal titer is obtained when GPE+Am12 is harvested as frequently as every 8 h while PG13-packaged vector titers appeared to be optimal at 24 h intervals. Unfortunately, we find that there is considerable variability among vector producer cell clones derived from the same packaging cell line. For example, about half of the The vector production facility (VPF) requires the sponsor to evaluate product at various stages of production to insure the vector maintains transgene function and to confirm the titer in the appropriate target cells. There is considerable variability among academic investigators in meeting the suggested timeframe for sponsor's listed above. product if the MCB has tested negative for these viruses and all serum and trypsin used in production is certified virus free.
Retroviral vector production at the NGVL K Cornetta et al producer cell lines derived from PG13 cells will provide optimal titer at 321C while half will provide optimal titer at 371C. Similarly, harvest times will vary between 8, 12, and occasionally 24 h for those MCBs derived from GPE+Am12 cells, while PG13-derived vector producer cell lines provide optimal titer when harvested at intervals between 12 and 24 h. This variability has led us to continue to individualize vector production conditions for producer cell lines. To this end, we perform small-scale roller bottle productions at 32 and 371C, with vector harvests at 8, 12, and 24 h (for PG13 we now limit harvests to 12 and 24 h). Five sequential harvests are tested and the titer is evaluated to select the optimal conditions for each MCB. This is performed in collaboration with the investigator to confirm our PCR titer data and to evaluate gene transfer efficiency in the appropriate target cells for the intended clinical application.
Vector production and certification
After the optimal harvest conditions are identified, a production run is initiated. One to two vials of cells from the MCB are expanded in flasks until sufficient numbers are obtained to inoculated approximately 40 roller bottles. Most investigators have requested between 10 and 40 l, which can be obtained in one or two production runs. Roller bottles have proven the most versatile given our volume needs, although many alternative systems are available and can likely be adapted to efficient vector production.
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After vector is harvested, another challenge is the efficient removal of cells and other debris without decreasing titer. Vector producer cells are known to release a variety of molecules and debris into the supernatant, some of which can affect vector titer. 12 Initially, investigators utilized commercially available filter systems ranging from 0.2 to 0.45 mm pore size which are well suited for processing small to moderate volumes of vector supernatant (less than a liter). Unfortunately, we observed that these filters can decrease titer and are not well suited to larger filtration volumes. For generating cell-free retroviral vectors, our laboratory explored the use of 'step filtration' where a series of blood banking filters of decreasing pore size are used to remove debris from the final product. 13 The advantage of such filters is that they are generally approved by regulatory agencies for use in humans, most components can be joined together using sterile connecting devices to form a closed system decreasing the risk of contamination, and can easily handle the volumes generated for most Phase I trials. As importantly, these 'step filtration' systems provide improved titer. The relative benefit of step filtration does vary and is clone dependent as we have observed significant variability in the amount of cell debris generated by an individual producer cell clone. Specifically, clones derived from the same packaging cell line often have significantly different filtration rates using 0.45 filters. For those products that pass relatively rapidly through the 0.45 mm filters, the benefit from step filtration is modest, about two-fold. For products that filter slowly, step filtration markedly improves titer (up to 10-fold). 13 After filtration, vector aliquots are dispensed using a closed system in volumes to meet the investigators needs, most often using FDA approved bags for storing hematopoietic cells for autologous transplantation. The final product undergoes a series of certification tests, the basic tests are listed in Table 3 . The material is maintained at À701C and shipped on dry ice through our institution's Investigational Drug Pharmacy. To ensure compliance with local and US federal regulations, we ship the material to the investigator's hospital pharmacy rather than shipping directly to the investigator.
Testing for replication-competent retrovirus
In mice, retroviruses cause malignancy by integrating near susceptible oncogenes and mediating overexpression of the oncogene, usually by the LTR enhancer (see Cornetta 14 for a review). This process is believed to require alterations in multiple oncogenes so that single vector integrations are believed to carry a very low risk of malignancy. Previously, the available data indicated that insertional mutagenesis after retroviral gene transfer would also be low, but not zero. 14, 15 Recently, a single vector integration near the LMO2 gene was associated with leukemia in two of 11 subjects participating in a gene therapy trial for X-linked severe combined immunodeficiency (SCID). [16] [17] [18] [19] The reasons why these children have developed leukemia while there were no cases of malignancy in prior retroviral gene therapy trials are complex, but preliminary evidence suggests the possibility that the transgene in this study (the common gamma chain cytokine receptor) is also acting as an oncogene (ie a second 'hit'). 20, 21 These adverse events with replication defective virus reinforce the importance of vigilant testing to exclude inadvertent contamination of vector products with replication-competent retrovirus (RCR). It is known that multiple integrations which occur when RCR is present result in insertional mutagenesis in mice and nonhuman primates. 14, 15 In retroviral vector products, the most likely source of RCR is recombination between the vector and viral genes used in vector packaging. RCR was frequently detected in early versions of vector packaging cell lines in which all the viral genes were expressed from a single plasmid. [22] [23] [24] [25] The rate of RCR generation has been decreased by minimizing sequence homology between vector and packaging cell sequences and the creation of split packaging cell lines that segregate gag-pol and env genes onto separate plasmids. [26] [27] [28] [29] [30] [31] Split packaging cell lines have successfully decreased the frequency of RCR generation from these packaging plasmids. However, a variety of novel RCRs have been generated which contain endogenous retroviral sequences. Chong et al LTR, gag and most of the pol genes in the RCR were derived from ecotropic endogenous retroviral sequences. Garrett et al 33 identified an RCR arising in a GP+ envAM12 producer cell line that was generated by transduction using an ecotropically packaged vector. The RCR contained the ecotropic envelope, which arose from a complicated sequence of recombination events, including endogenous sequences carried over from ecotropic producer cell line GPE+E86. These data indicate that when RCR develops it is likely to arise after multiple recombinations and may contain endogenous sequences. The incidence is likely to be less when Retroviral vector production at the NGVL K Cornetta et al using human cell lines to generate vector, although the possibility of recombination with human endogenous retroviral sequences must be considered. Interestingly, we have noted the development of RCR in the amphotropic packaging cell lines PA317 and GPEAm12 but have yet to detect RCR in productions using the PG13 cell line. As PG13 contains the GALV envelope, and murine cell lines such as PG13 lack the receptor for this envelope, the inability of a packaging cell line to reinfect itself may play a role in minimizing RCR development.
To date, the detection of RCR in vectors intended for clinical use relies on a combination of biologic assays and molecular detection. In the US, the recommended biologic assays are the extended S+/LÀ assay and the marker rescue assay, both of which amplify virus on a permissive cell line. 34 In the S+/LÀ assay, amplified virus is then evaluated on an indicator cell line, such as the cat cell line PG-4. [35] [36] [37] [38] [39] [40] The PG-4 cell line is referred to as a S+/LÀ cell line, for sarcoma positive (S+) and leukemia negative (LÀ). PG-4 cells contain the murine sarcoma virus genome, which can induce a transformed phenotype but only in cells also expressing a murine leukemia virus. If the test material contains RCR, foci of transformed cells can be detected on lawns of PG-4 cells. By performing limiting dilution of the test material, the amount of virus in the test material can be quantified. In contrast, the marker rescue assay uses a cell line containing a vector that is then mobilized in the presence of an RCR, passage of the marker transgene to an indicator cell provides evidence of an RCR.
Initial methods for RCR testing were developed to detect vector pseudotyped with the amphotropic envelope derived from the murine leukemia virus 4070A. [36] [37] [38] [39] [40] [41] [42] [43] Pseudotyping is the term given to re-engineering of viral or vector particles where the native envelope glycoprotein is replaced with that of another virus. For example, the Moloney Murine Leukemia Virus (MoMLV) used as the basis for most retroviral vector is an ecotropic virus. The ecotropic envelope receptor is expressed on murine and other rodent cells but not on human cells. The 4070A envelope is classified as amphotropic since its receptor is expressed on a wide variety of mammalian cells. Pseudotyping MoMLV particles with this glycoprotein allow infection of human cells. Screening for RCR requires attention to the envelope glycoprotein most likely to be on the RCR particles. For example, Mus dunni cells have been used to amplify RCRs containing the 4070A envelope since this cell line is permissive to the widest variety of amphotropic viruses. In contrast, Mus dunni is an unusual murine cell line in that it is relatively resistant to infection by the MoMLV and is therefore unsuitable for amplifying ecotropic RCR. Currently, we utilize NIH3T3 cells when screening for ecotropic RCR. 44 A variety of other glycoproteins have been explored as alternatives to the 4070A envelope. One that has now been used in a variety of clinical applications is the envelope derived from the Gibbon Ape Leukemia Virus (GALV). The GALV envelope has demonstrated improved transduction efficiency in a number of target cells, in part, due to the increased expression of the GALV receptor on these cells. 31, [45] [46] [47] [48] [49] The GALV envelope acts as a xenotropic virus in that it infects primate but not murine cells. 31 Therefore, current assays for detection of amphotropic RCR are not suitable for GALV RCR detection. To address this, our laboratory has adapted the extended S+/LÀ assay by substituting 293 cells for Mus dunni and found similar levels of virus detection. 50 Another retroviral envelope being developed for clinical trial use was cloned from the RD114 virus, which also displays properties of xenotropic viruses. [51] [52] [53] [54] [55] The 293 cell line is also useful for amplifying RD114 pseudotyped RCR in an extended S+/LÀ assay. 56 Finally, when an RCR is detected the most likely source will be through recombination but one must also consider other sources of virus. For example, in the course of human gene transfer trials, Miller et al 40 and Miller and colleagues 57 identified a novel retrovirus which they named the Mus dunni endogenous virus MDEV. The MDEV virus was present in the Mus dunni cell line used in a marker rescue assay and was activated by hydrocortisone in the hematopoietic cell growth medium of the test cells. Therefore, cell lines used for amplification and assay must be considered as a possible source of RCR unrelated to the vector product being tested.
PCR screening for RCR
Recommendations by the US FDA include monitoring of patients for RCR for up to 15 years after vector exposure. 34 PCR is often the most practical and easiest method and various assays have been developed by a number of investigators. Care must be taken in the samples selected for testing by the PCR method, a lesson we learned during the course of a human clinical gene therapy trial. In that study, we were asked by the FDA to test transduced autologous peripheral blood stem cells (PBSC) prior to their reinfusion. We detected 4070A viral envelope sequences in CD34+ PBSC 2 days after transduction, suggesting the presence of RCR. The supernatant and producer cells used for vector generation had been negative in extensive screening using the extended S+/LÀ assay. The presence of a replication competent virus was subsequently excluded by a combination of biologic and PCR analyses. 58 The source of the 4070A viral envelope sequences was determined to be packaging cell line DNA in the vector supernatant. The analysis of a variety of vector supernatants by quantitative real-time PCR revealed 4070A envelope DNA sequences from the packaging cell line in concentrations equivalent to approximately 50-500 focus forming units/ml of wild-type 4070A virus. Our data indicate that PCR should not be used to analyze transduced cells for RCR within the first two weeks of vector exposure. 58 Furthermore, investigators using PCR to analyze transduction efficiency shortly after vector exposure may experience false positive findings.
Future challenges
While the majority of vector production requests to the NGVL have been from murine-based packaging cell lines, alternate production systems have also been developed and may have certain advantages. Reports of improved titer have been published for stable human and canine-based packaging cell lines. 59, 60 These lines may not produce inhibitory proteoglycans or other factors known to decrease the functional titer from NIH3T3-derived packaging cell lines. 12, 59 Transient production systems can yield high titer supernatant and do not require the lengthy process of identifying a high titer producer cell clone typical of most stable packaging cell line systems. 61 Pseudotyping with the vesicular stomatitis virus envelope G (VSV-G) protein has the potential advantage of facilitating concentration of the virus, thereby increasing titer. While stable packaging cell lines using this envelope have been reported, [62] [63] [64] [65] most investigators using VSV-G utilize transient production systems due to the toxicity associated with expression of the VSV-G envelope protein. Interestingly, the NGVL has received only one request for retroviral production by transient transfection methods. This suggests investigators wishing to pursue clinical trials continue to find advantages in the consistency and detailed characterization afforded by stable packaging cell lines.
Concentration and purification methods for vectors can also provide a product with increased titer 66, 67 and may eliminate the need for filtration. 68, 69 Unfortunately, the fragile state of the retroviral vectors results in loss of particles during concentration so the actual yield of vector particles is much lower than the amount produced, adding significantly to the cost of production. While improved vector production technology is needed, generation of vector from producer cell lines by the methods described above are still likely to be utilized for many Phase I studies. This is related in part to the cost advantages, and to recent improvements in transduction methodology allowing clinically significant transduction of target cells with unconcentrated retroviral vector. 16, 70 Our observations serve as a practical guide for investigators generating retroviral vectors who wish to optimize their titer results. While certain generalizations have been observed, our data suggests that maximizing vector titer requires individualized assessment of the producer cell line, including assessments of optimal harvest time and incubation temperatures. As clinical trials move from Phase I and II studies, the volumes and characterizations associated with Phase III and licensed products will require more sophisticated production methods and postharvest processing. New vector pseudotypes such as RD114 and VSV-G hold promise for improved methods of vector concentration and higher titers. Finally, whether vector redesign can overcome the limitations of insertional mutagenesis and cell cycle requirements for integration remain challenges critical to the ultimate success of these vectors in clinical gene transfer.
